Carboplatin in ovarian cancers;Carboplatine dans les cancers de l'ovaire

Bulletin du Cancer

Volumn 87, Issue SPEC. ISS. AUG., 2000, Pages 40-47

  Pujade Lauraine, E ^a   Guastalla, J P ^a   Vincent, P ^a  

^a HÔTEL DIEU   (France)

Author keywords

Carboplatin; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

AREA UNDER THE CURVE; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; META ANALYSIS; OVARY CANCER; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; ATTITUDE OF HEALTH PERSONNEL; CARBOPLATIN; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; HUMANS; META-ANALYSIS; OVARIAN NEOPLASMS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; THROMBOCYTOPENIA;

EID: 0033811421     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Long-term follow up of the first randomised study of cisplatin versus carboplatin for advanced epithelial ovarian cancer
2. A comparison of toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer
3. Randomised trial in advanced ovarian cancer comparing cisplatin and carboplatin
4. Comparitive toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer
5. Carboplatin in combination chemotherapy for ovarian cancer
6. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma : A comparison of equally myelosuppressive regimens
7. Carboplatin, doxorubicin and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide : A randomised trial in stage III-IV epithelial ovarian carcinoma
8. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer : A randomised phase III study of the National Cancer Institute of Canada Clinical Trials Group
9. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide : Final report by the Southwest Oncology Group of a phase III randomised trial in stages III and IV ovarian cancer
10. Cyclophosphamide/cisplatin (CTX/PT) vs CTX/carboplatin (CarboPT) in advanced ovarian carcinoma : A randomised multicentre study
11. Carboplatin, epirubicin and cyclophosphamide versus cisplatin, epirubicin and cyclophosphamide : A phase III randomised trial in stages III and IV epithelial ovarian cancer
12. Phase III study of carboplatin for ovarian cancer
13. Chemotherapy in advanced ovarian cancer an overview of randomised clinical trials
14. Chemotherapy in advanced ovarian cancer : Four systematic meta-analysis of individual patient data from 37 randomized trials
15. Advanced ovarian cancer : Carboplatin versus cisplatin
16. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer
17. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer : Mature results of the EORTC-GCCG. NOCOVA, NCIC CTG and Scottish Intergroup trial
18. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB-IV, comparing paclitaxel/cisplatin and paclitaxel/carboplatin
19. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer : Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Trial
20. Randomized phase III of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC) : A Gynecologic Oncology Group Trial (GOG 158)
21. A new standard of care for treatment of ovarian cancer
22. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
23. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma : A comparison of equally myelosuppressive regimens
24. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer
25. Dose-effect study of carboplatin in ovarian cancer : A Danish Ovarian Cancer Group Study
26. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer : Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels
27. Carboplatin and paclitaxel in patients with advanced ovarian cancer : A dose-finding study
28. High dose chemotherapy with hematopoietic stem cell support as consolidation therapy for patients with platinum-sensitive advanced epithelial ovarian cancer : A retrospective study of 181 patients from six French centers
29. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma
30. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer
31. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer : A multivariate analysis of survival for 100 consecutively treated patients
32. High-dose chemotherapy as first line treatment in ovarian cancer : A phase II study
33. Clinical and in vitro effects of recombinant human erythropoeietin in patients receiving intensive chemotherapy for small-cell lung cancer
34. Second-line chemotherapy in epithelial ovarian carcinoma : Platinium again ? taxanes ? how to choose
35. Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer
36. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer
37. Optimal carboplatin (CBDCA) dosage calculation when combined with paclitaxel (P) : A randomized trial of AUC vs BSA in patients (pts) with relapsed ovarian cancer (OC)
38. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
39. Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy : A multicenter study of the French Federation nationale des centres de lutte contre le cancer
40. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer
41. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy